Long-term Follow-up Results From the Phase 2 Multicenter Study of Ublituximab(UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients With Relapsing Multiple Sclerosis (RMS)

Drug Category : Array
Conference Category : Array
Lead Author : Fox E, et al.
Published Date : 27/02/2020
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2020/03/Final-ACTRIMS-2020-Poster-FOX.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top